- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04264845
Patient-Reported Outcomes as an Indicator of Disease Transitions in Heart Failure (PRO-HF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint of this study is the determination of the feasibility and efficiency of integrating routine PRO assessments into the clinical care of patients treated for HF. To reach this, three groups will be involved in the study.
Provider Focus Group (n = 40):
Following obtaining their agreement to participate, the Providers will be given a date, time, and venue for his/her participation in the focus group and will meet for one hour. An agenda and script for the conduct of the focus group session will be developed by a trained moderator. The focus groups will be conducted by a member of the research team. Data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of patient-reported outcomes (PROs) and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12 month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
Patient Interview Group (n = 100):
Following obtaining agreement to be interviewed, a trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had left ventricular assist device (LVAD) therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
PROs/Clinical Data Integration Group (n = 3500):
The patients' electronic medical records will be reviewed and protocol-required information will be obtained. PRO capture will be expanded in a large population of patients across the continuum of HF patients. A plan has been developed that will integrate PRO scores into their medical records. Information will be obtained from 2 instruments (Kansas City Cardiomyopathy Questionnaire (KCCQ12) and NIH Patient Reported Outcomes Measurement Information System (PROMIS)) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic during the study period. Patient information will be stored in a secure research database. The data will be used to build prognostic models of 1-year survival with favorable quality of life in patients with various forms of heart failure.
No follow-up visits will be required for the PROs/Clinical Data Integration Group. All protocol-required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
Biologic Determinants of Patient Health Status in HF (n = 1000):
Subjects in the Integration Group that meet the inclusion criteria for this subject subset will be contacted in person by the Principal Investigator or his/her delegate. Subjects will be asked if they are willing to provide their blood samples.
Blood samples will be obtained approximately every six months for the duration of the study (i.e., about 4 years). Approximately 40 ml (or 2.71 tablespoons) of venous blood will be obtained on each scheduled blood draw.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Utah
-
Murray, Utah, United States, 84143
- Intermountain Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All heart failure providers at the Intermountain Medical Center are potential participants in the Provider Focus Group.
Patients with heart failure who are seen in the HF outpatient clinics at Intermountain Medical Center are potential participants in the Patient Interview Group or the PROs/Clinical Data Integration Group.
Description
Inclusion Criteria:
Eligible participants in the Provider Focus Group and Patient Interview Group:
- Male or female > 18 years of age
- Ability to understand and provide agreement to participation, which must be obtained prior to initiation of any study procedures
- Willing and able to comply with the protocol requirements and schedule of evaluations
The Provider Focus Group must meet the following additional criteria:
- Heart failure providers, including cardiologists, cardiothoracic surgeons, physician assistants, nurse practitioners, nurses, and medical assistants.
- They are members of the University of Utah and/or Intermountain Medical Center Heart Failure Teams.
The Patient Interview Group must meet the following additional criteria:
- Documentation of heart failure with reduced ejection fraction (<50%) or heart failure with preserved ejection fraction (>50%)
- The patient is followed in heart failure clinic at Intermountain Medical Center or the University of Utah
- Ability to complete PROs, including the KCCQ12 and PROMIS
- Ability to complete a telephone interview
The PROs/Clinical Data Integration Group must meet the following criteria:
- Male or female > 18 years of age
- Documentation of heart failure with reduced ejection fraction (<50%) or heart failure with preserved ejection fraction (>50%)
- The patient is followed in heart failure clinic at Intermountain Medical Center or the University of Utah
- No other inclusion criteria are required for this group because study-required information will be obtained from electronic medical records and will not require direct patient contact.
A subset of subjects in this third group (PROs/Clinical Data Integration Group) will be invited to provide a blood sample for the purpose of examining the biological determinants of patient health status in HF, provided they meet the following criteria:
- Age > 18
- Documentation of heart failure with reduced ejection fraction (<50%) or heart failure with preserved ejection fraction (>50%)
- The patient is followed in heart failure clinic at Intermountain Medical Center or the University of Utah
- The patient has no contraindications for blood draws
Exclusion Criteria:
Provider Focus Group:
- The provider is not interested or is unable to participate in the focus group
- The Principal Investigator determines that the provider is not eligible for this research study
Patient Interview Group:
- The patient is not willing to be interviewed
- Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study
- Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial
- The Principal Investigator determines that the proposed patient is not eligible for this research study
PROs/Clinical Data Integration Group:
- Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study
- Other conditions that in the opinion of the Principal Investigator may compromise the quality of the clinical trial
- The Principal Investigator determines that the proposed patient is not eligible for this research study
A subset of subjects in this third group (PROs/Clinical Data Integration Group) will be invited to provide a blood sample for the purpose of examining the biological determinants of patient health status in HF, except the following:
- Patients who are not interested in providing blood samples
- Patients without heart failure
- Patients with contraindications to blood draws
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Provider Focus Group
All heart failure providers at the participating centers will be screened as potential participants.
|
The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care.
A formal provider training program will be designed and implemented by a subject matter expert.
The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
|
Patient Interview Group
Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study.
The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria.
A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
|
A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants.
Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation.
The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
|
PROs/Clinical Data Integration Group
Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles. This group includes a sub-study of patients providing blood samples. |
A plan has been developed that will integrate PRO scores into patient medical records.
Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care.
PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic.
All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time necessary for PRO completion by patients
Time Frame: 4 years
|
It is believed that data entry requirement below 10 minutes is conducive to patient participation and will not interfere with clinic flow.
This will me monitored throughout the trial.
|
4 years
|
Completion rate among eligible patients
Time Frame: 4 years
|
PRO completion rate will be closely monitored throughout the study.
It is anticipated that the completion rate will exceed 80% and will be sustainable over time.
|
4 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1050750
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on Provider Focus
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)Active, not recruiting
-
University of Wisconsin, MadisonRecruitingEmotions | Psychological Stress | Physiological StressUnited States
-
IpasSt. Paul's Hospital Millennium Medical College, Addis Ababa, EthiopiaCompletedMedical Abortion | Induced Abortion | Second Trimester Abortion | Health PersonnelEthiopia
-
University of MichiganNational Cancer Institute (NCI); Wayne State University; Barbara Ann Karmanos... and other collaboratorsCompletedBreast Cancer | Colorectal Cancer | Lung Cancer | Prostate CancerUnited States
-
Albert Einstein College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBreastfeeding | Breastfeeding, ExclusiveUnited States
-
Nantes University HospitalUnknown
-
Federal University of Health Science of Porto AlegreCompletedMuscle Weakness | Muscle Weakness Condition | Neck; AnomalyBrazil
-
University of South FloridaNational Cancer Institute (NCI)Completed
-
Queen's University, BelfastCompletedAge Related Macular DegenerationUnited Kingdom
-
The University of Texas Health Science Center,...Baylor College of Medicine; Cancer Prevention Research Institute of TexasCompletedHuman Papillomavirus (HPV)United States